India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>JSW Steel Reports 5% YoY Production Growth Amid Financial Pressure.</li>
<li>Vodafone Idea to Raise INR 1,980 Crore via Preferential Shares.</li>
<li>Metropolis Healthcare to Acquire Core Diagnostics for INR 247 Crore</li>
</ul>


JSW Steel Reports 5% YoY Production Growth Amid Financial Pressure.
Vodafone Idea to Raise INR 1,980 Crore via Preferential Shares.
Metropolis Healthcare to Acquire Core Diagnostics for INR 247 Crore


# 72 India Insight: VI Preferential Issue, JSW Production Growth, Metropolis Acquisition of Core

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Suraksha Diagnostic / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/suraksha-diagnostic" target="_blank" data-smartkarma-citation="entities:43795:1" rel="noopener">Suraksha Diagnostic (1481262D IN)</a> offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services in Eastern and North Eastern states of India.</li>
<li>The IPO comprises only an offer for sale of up to 19M equity shares, with no fresh issue. Suraksha Diagnostic has set price band of INR420–441 per share.</li>
<li>The floor price of the IPO reflects fair value of the company and discounts all near-term growth catalyst. We would advise not to subscribe the issue for listing gain.</li>
</ul>



Suraksha Diagnostic (1481262D IN) offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services in Eastern and North Eastern states of India.
The IPO comprises only an offer for sale of up to 19M equity shares, with no fresh issue. Suraksha Diagnostic has set price band of INR420–441 per share.
The floor price of the IPO reflects fair value of the company and discounts all near-term growth catalyst. We would advise not to subscribe the issue for listing gain.


Suraksha Diagnostic IPO: Premium Valuation Limits Near-Term Upside Potential

External broker reports(aggregated public sources), Emkay Global Financial Services Limited

Emkay

External broker reports(aggregated public sources)

Emkay Global Financial Services Limited

Emkay Global Financial Services Ltd. is a leader in the financial services sector, actively creating wealth for our clients for over two decades. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Metropolis Healthcare Limited / Equity Bottom-Up

<ul><li>MHL’s Q2FY25 print was in line with our estimates, with revenues growing 13% YoY, driven by B2C revenues improving 21% YoY.</li><li>Overall sample volume growth (8%) was dragged by the B2B portfolio as MHL rationalized its long tail customers.</li><li>Tier 3 revenue growth of 23% is encouraging given the investments made by MHL over the last 3-4 years.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

MHL’s Q2FY25 print was in line with our estimates, with revenues growing 13% YoY, driven by B2C revenues improving 21% YoY.Overall sample volume growth (8%) was dragged by the B2B portfolio as MHL rationalized its long tail customers.Tier 3 revenue growth of 23% is encouraging given the investments made by MHL over the last 3-4 years.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Metropolis Healthcare - Tier 3 Expansion and Wellness Portfolio to Drive Revenue Growth

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Shree Cement: We maintain our ADD rating on Shree Cement, with an unchanged SOTP target price of INR 26,700/share</li><li>During Q2FY25, Shree volume declined 7% YoY as it focused on trade sales while non-trade demand was weak</li><li>Cement NSR fell only 0.4% QoQ, lower vs peers owing to rise in trade sakes QoQ</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Shree Cement: We maintain our ADD rating on Shree Cement, with an unchanged SOTP target price of INR 26,700/shareDuring Q2FY25, Shree volume declined 7% YoY as it focused on trade sales while non-trade demand was weakCement NSR fell only 0.4% QoQ, lower vs peers owing to rise in trade sakes QoQContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Shree Cement, Aurobindo Pharma, Gujarat State Petronet

<ul><li>The India Pharma &amp; Healthcare sector is expected to maintain its growth momentum in Q2FY25E</li><li>We project sales/EBITDA growth of 11%/15% YoY for our coverage universe</li><li>Our assumptions are: (1) Pharma coverage is expected to see 11% YoY sales growth, driven by a 12% YoY increase in the India business, offset by a ~5% QoQ decline in the US</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The India Pharma &amp; Healthcare sector is expected to maintain its growth momentum in Q2FY25EWe project sales/EBITDA growth of 11%/15% YoY for our coverage universeOur assumptions are: (1) Pharma coverage is expected to see 11% YoY sales growth, driven by a 12% YoY increase in the India business, offset by a ~5% QoQ decline in the USContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise

India

Metropolis Healthcare Limited provides medical and laboratory services. The Company offers pathology testing, imaging and nuclear medicine, clinical trails, and home health services. Metropolis Healthcare operates chains of diagnostic centers across India.

Metropolis Healthcare Limited (METROHL IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Metropolis Healthcare Limited (METROHL IN)

# 72 India Insight: VI Preferential Issue, JSW Production Growth, Metropolis Acquisition of Core

JSW Steel sees production growth, Vodafone Idea to raise funds through Preferential issue, Metropolis Healthcare acquires Core Diagnostics.

Sudarshan Bhandari

Suraksha Diagnostic IPO: Premium Valuation Limits Near-Term Upside Potential

Suraksha Diagnostic offers integrated pathology and radiology services in India. The IPO comprises of an OFS of up to 19M shares. The company has...

Tina Banerjee

Metropolis Healthcare - Tier 3 Expansion and Wellness Portfolio to Drive Revenue Growth

MHL’s Q2FY25 print was in line with our estimates, with revenues growing 13% YoY, driven by B2C revenues improving 21% YoY.

Emkay

HSIE Results Daily: Shree Cement, Aurobindo Pharma, Gujarat State Petronet

During Q2FY25, Shree volume declined 7% YoY as it focused on trade sales while non-trade demand was weak. Cement NSR fell only 0.4% QoQ, lower vs...

HDFC Securities

Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise

The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our...

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

# 72 India Insight: VI Preferential Issue, JSW Production Growth, Metropolis Acquisition of Core

​JSW Steel sees production growth, Vodafone Idea to raise funds through Preferential issue, Metropolis Healthcare acquires Core Diagnostics.

Sudarshan Bhandari

Suraksha Diagnostic IPO: Premium Valuation Limits Near-Term Upside Potential

​Suraksha Diagnostic offers integrated pathology and radiology services in India. The IPO comprises of an OFS of up to 19M shares. The company has...

Tina Banerjee

Metropolis Healthcare - Tier 3 Expansion and Wellness Portfolio to Drive Revenue Growth

MHL’s Q2FY25 print was in line with our estimates, with revenues growing 13% YoY, driven by B2C revenues improving 21% YoY.

Emkay

HSIE Results Daily: Shree Cement, Aurobindo Pharma, Gujarat State Petronet

During Q2FY25, Shree volume declined 7% YoY as it focused on trade sales while non-trade demand was weak. Cement NSR fell only 0.4% QoQ, lower vs...

HDFC Securities

Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise

The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our...

HDFC Securities

JSW Steel sees production growth, Vodafone Idea to raise funds through Preferential issue, Metropolis Healthcare acquires Core Diagnostics.

Suraksha Diagnostic offers integrated pathology and radiology services in India. The IPO comprises of an OFS of up to 19M shares. The company has...